This Treatment Improvement Protocol (TIP) provides guidance to counselors, administrators, and supervisors about recovery-oriented services, supports, and care, allowing them to better serve individuals in or seeking recovery from problematic substance use.

This report provides key findings from the 2022 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment among the noninstitutionalized U.S. population aged 12 or older. Estimates are presented by age group and by race/ethnicity for selected measures.

This TIP supports learning about the key aspects, functions, and uses of Peer Support Services (PSS) in recovery from problematic substance use, which will help providers, supervisors, and administrators in SUD treatment programs better understand and respond to these changes.

Read key findings from the 2021 National Survey on Drug Use and Health (NSDUH) on substance use, mental health, and treatment. Metrics in the report cover the civilian, noninstitutionalized US population ages 12 and older. Estimates are presented by age group and by race/ethnicity for selected measures. Unlike other NSDUH Annual National Reports, the 2021 report has no discussion of trends over time, because changes in survey methodology mean the indicators are not comparable to past NSDUH estimates.

This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This chartbook uses combined 2015 to 2019 data from the National Survey on Drug Use and Health (NSDUH) to present nationally representative estimates of mental health service utilization among adults aged 18 or older and adolescents aged 12 to 17 within different racial/ethnic groups in the United States. The percentages are annual averages.

This Advisory is based on TIP 60, Using Technology-Based Therapeutic Tools in Behavioral Health Services. It provides information on synchronous and asynchronous telehealth technologies for behavioral health treatment. Factors such as technology access and implementation are addressed.

This Advisory is based on TIP 42, Substance Use Disorder Treatment for People with Co-Occurring Disorders. It highlights strategies for counselors and administrators to properly screen, assess, diagnose, and manage the treatment of individuals with co-occurring substance use and mental disorders.